In accordance with the data provided by several past studies in other malignancies, PC patients with higher levels of MCM2, MCM4 and MCM 6 had poorer outcomes (MCM2, 4, and 6 for disease free survival time and MCM2 and 2 for overall survival time). Here, MCM2 is linked to pachyonychia congenita.